Mercury poisoning: The Company is working to obtain marketing authorization in the EU and the US for the treatment of mercury toxicity, for which Orphan Drug Designation has been obtained in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed. Phase 2b/3 is planned for fall 2017.
COPD: A Phase 2a clinical trial is ongoing for the treatment of COPD and finished by December 2017.
Other conditions: Preclinical studies ongoing for other indications.
Expanded access/Early access: A SwissMedic (Switzerland) and FDA (USA) have approved Irminix® for Named Patient/Compassionate use. More information under Resources.
Subscribe To Our Mailing List: (* indicates required)